Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Key Highlights
- ➤Decipher predicted abiraterone benefit in very high-risk prostate cancer; interaction p=0.01
- ➤High Decipher scores showed 10% five-year distant-metastasis benefit from abiraterone
- ➤Very high Decipher scores showed 11% five-year distant-metastasis benefit from abiraterone
- ➤Lower Decipher scores showed just 2% five-year distant-metastasis benefit
- ➤STAMPEDE analysis included 401 patients receiving ADT alone or with abiraterone
Expert Statements
Sarah Howlett, Clinical research fellow, Research Department of Oncology, University College London
“For men with very high-risk disease, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference”
Sarah Howlett, Clinical research fellow, Research Department of Oncology, University College London
“This analysis shows that the Decipher test can identify which patients in this study population were at greatest risk of prostate cancer-specific mortality and, therefore, may gain the greatest benefit from adding abiraterone to ADT. That gives physicians and patients evidence to make more confident treatment decisions based on the biology of the individual tumor.”
Elai Davicioni, Medical director, Urology, Veracyte
“These findings expand Decipher’s predictive evidence to another consequential treatment decision: whether adding abiraterone will provide meaningful benefit for a man with very high-risk prostate cancer”
Elai Davicioni, Medical director, Urology, Veracyte
“Building on the predictive data recently presented in intermediate-risk disease at ASTRO, these results strengthen Decipher’s role in helping physicians connect tumor biology to treatment selection across the prostate cancer risk continuum. We believe this growing evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life.”
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The findings will be presented tomorrow in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 by Dr. Sarah Howlett of University College London (UCL).
The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This predictive evidence bolsters Decipher’s high-risk claims to help physicians identify which patients are most likely to benefit from adding abiraterone to ADT. These findings build on Decipher’s long-established standing in guidelines for assessing the risk of cancer progression, as well as prior STAMPEDE analysis that was recently incorporated into the NCCN 2027 prostate cancer guidelines for high- and very high-risk disease.
Get started
Create a free account to read the full story.